Menu
Oncoguard Liver logo
hero-hcp

An HCC test with 82% early-stage sensitivity? Exactly.

Join us in making earlier HCC detection a reality. The Oncoguard® Liver solution includes a simple, multi-target blood test that delivers 88% sensitivity and 87% specificity.

Exactly the performance you need.

  Jump to a section:

exs-lvr-Icon-EfficientAdvanced performance you can rely on
exs-lvr-icon-innovationInnovation without inconvenience
exs-lvr-icon-supporting-the -careSupport that drives adherence

The Oncoguard® Liver solution reflects visionary collaboration between committed partners aiming to raise the standard of HCC surveillance

The solution includes a sophisticated, yet simple, blood test that demonstrates strong performance for the detection of early-stage HCC. The test is complemented by a Patient Engagement Program designed to help empower patients to proactively protect their health and follow through with ongoing testing. Together, the Oncoguard® Liver solution offers a streamlined approach to HCC detection and support to help more patients access the vital testing they need.

The Oncoguard® Liver solution is more than a blood test

Advanced performance you can rely on

Now, there is a new approach to detection for early-stage HCC.

Built upon three essential ideas of performance, access, and adherence, the Oncoguard® Liver solution is far more than a routine lab test. The Oncoguard® Liver solution offers a revolutionary way to approach and detect early-stage HCC.

What makes the Oncoguard® Liver solution a leader in performance? There are several key components:



exs-lvr-Icon-Validation

Robust scientific platform

The Oncoguard® Liver test was built on a clinical development platform that was robustly designed in collaboration with leading experts to provide reliable results that translate into real-world clinical practice for confidence in HCC detection.

exs-lvr-Icon-Early-Stage-Detection

A novel approach to accurate early-stage detection

The Oncoguard® Liver test delivers a high level of accuracy using a unique set of markers carefully selected to detect early-stage disease in patients at risk of developing HCC.

exs-lvr-Icon-Report

Actionable results

With high sensitivity and specificity to detect early-and all-stage HCC and easy-to-interpret qualitative results,1 the Oncoguard® Liver test empowers you to take action sooner so that the goal of achieving long-term survival may be within reach for more of your patients.

content-image-7

Innovation without inconvenience

By streamlining the process, we’ve made it more attainable for more people.

Simple, yet sophisticated blood test

A single test sophisticated enough to detect early-stage HCC offers a streamlined approach to routine HCC testing,1 helping patients get the vital testing they need without the hassle.

Convenient collection

Ongoing HCC testing can be achieved with one test in one location, so patients can bypass the logistical challenges often faced with traditional surveillance methods2 and follow through with their care.

illustration test

Support that drives adherence

We understand that ensuring patients adhere to the testing that is essential to detecting HCC in its early stages is key to improving outcomes for patients at risk. That’s why we’re relentlessly focused on support.



exs-lvr-icon-support-for-patient

Support for the Patient

The Oncoguard® Liver solution Patient Engagement Program includes patient-friendly educational content and testing reminders aimed at encouraging patients to adhere to their physician-recommended testing schedule and empowering them to play an active role in staying ahead of their disease.

exs-lvr-icon-supporting-the -care

Supporting the care you deliver

Knowing HCC testing doesn’t just happen—the Oncoguard® Liver Patient Engagement Program complements your own encouragement, reassurance, and patient management, with the aim of helping you achieve the goal of improving outcomes for more patients.

The Oncoguard® Liver solution. Exactly what’s needed today.

Learn more about the Oncoguard® Liver test.

Learn More

References: 1. Chalasani NB, Bhattacharya A, Book AJ, et al. Improved sensitivity for early-stage hepatocellular carcinoma detection with a novel blood-based panel of methylated DNA and protein markers. Presented at the American Society of Clinical Oncology Annual Meeting; May 29th-June 2, 2020. 2. Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2017;65(3):875-884. doi:10.1002/hep.28770